Chronic dietary toxicity and carcinogenicity study with ammonium perfluorooctanoate in Sprague-Dawley rats

Toxicology

Volumn 298, Issue 1-3, 2012, Pages 1-13

  Butenhoff, John L ^a   Kennedy Jr , Gerald L ^b   Chang, Shu Ching ^a   Olsen, Geary W ^a  

^a 3M COMPANY   (United States)

^b DUPONT COMPANY   (United States)

Author keywords

APFO; Dietary; Oncogenicity; Perfluorooctanoate; PFOA; Rats

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; PERFLUOROOCTANOATE AMMONIUM; PERFLUOROOCTANOIC ACID; UNCLASSIFIED DRUG;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY WEIGHT; CARCINOGENICITY; CELL INFILTRATION; CHRONIC TOXICITY; CONTROL GROUP; CONTROLLED STUDY; FEMALE; LEYDIG CELL; LEYDIG CELL TUMOR; LIVER HYPERTROPHY; LIVER NECROSIS; LIVER WEIGHT; MALE; NONHUMAN; ORGAN WEIGHT; PRIORITY JOURNAL; RAT; SURVIVAL; TESTIS;

ANIMALS; BODY WEIGHT; CARCINOGENICITY TESTS; DIET; FEMALE; FLUOROCARBONS; LIVER; MALE; OCTANOIC ACIDS; ORGAN SIZE; RATS; RATS, SPRAGUE-DAWLEY; SURVIVAL RATE;

RATTUS;

EID: 84861920551     PISSN: 0300483X     EISSN: 18793185     Source Type: Journal    
DOI: 10.1016/j.tox.2012.04.001     Document Type: Article

References (52)

1. Amacher D.E. Serum transaminase elevations as indicators of hepatic injury following the administration of drugs. Regul. Toxicol. Pharmacol. 1998, 27:119-130.
2. Anderson V.L., McLean R.A. Design of Experiments: a Realistic Approach 1974, Marcel Dekker, New York.
3. Bentley P., Calder I., Elcombe C., Grasso P., Stringer D., Wiegand H.J. Hepatic peroxisome proliferation in rodents and its significance for humans. Food Chem. Toxicol. 1993, 31:857-907.
4. Biegel L.B., Liu R.C., Hurtt M.E., Cook J.C. Effects of ammonium perfluorooctanoate on Leydig cell function: in vitro, in vivo, and ex vivo studies. Toxicol Appl Pharmacol 1995, 134:18-25.
5. Biegel L.B., Hurtt M.E., Frame S.R., O'Connor J.C., Cook J.C. Mechanisms of extrahepatic tumor induction by peroxisome proliferators in male CD rats. Toxicol. Sci. 2001, 60:44-55.
6. Bjork J.A., Wallace K.B. Structure-activity relationships and human relevance for perfluoroalkyl acid-induced transcriptional activation of peroxisome proliferation in liver cell cultures. Toxicol. Sci. 2009, 111:89-99.
7. Bjork J.A., Butenhoff J.L., Wallace K.B. Multiplicity of nuclear receptor activation by PFOA and PFOS in primary human and rodent hepatocytes. Toxicology 2011, 288:8-17.
8. Boone l., Meyer D., Cusick P., Ennulat D., Bolliger A.P., Everds N.E., Meador V., Elliott G., Honor D., Bounous D., Jordan H. Selection and interpretation of clinical pathology indicators of hepatic injury in preclinical studies. Vet. Clin. Pathol. 2005, 34:182-188.
9. Butenhoff J.L., Kennedy G.L., Frame S.R., O'Connor J.C., York R.G. The reproductive toxicology of ammonium perfluorooctanoate (APFO) in the rat. Toxicology 2004, 196:95-116.
10. Car B.D., Eng V.M., Everds N.E., Bounous D.J. Clinical pathology of the rat. The Laboratory Rat 2006, 135. Elsevier Academic Press, London. second ed. M.A. Suckow, S.H. Weisbroth, C.L. Franklin (Eds.).
11. Conover W.J. Practical Nonparametric Statistics 1971, John Wiley and Sons, New York.
12. Conover W.J., Iman R.L. Rank transformations as a bridge between parametric and nonparametric statistics. Am. Stat. 1981, 35:124-129.
13. Doull J., Cattley R., Elcombe C., Lake B.G., Swenberg J., Wilkinson C., Williams G., van Gemert M. A cancer risk assessment of di(2-ethylhexyl)phthalate: application of the new U.S. EPA Risk Assessment Guidelines. Regul. Toxicol. Pharmacol. 1999, 29:327-357.
14. Dunnett C.W. New tables for multiple comparisons with a control. Biometrics 1964, 20:482-491.
15. Elcombe C.R., Elcombe B.M., Foster J.R., Farrar D.G., Jung R., Chang S.C., Kennedy G.L., Butenhoff J.L. Hepatocellular hypertrophy and cell proliferation in Sprague-Dawley rats following dietary exposure to ammonium perfluorooctanoate occurs through increased activation of the xenosensor nuclear receptors PPARα; and CAR/PXR. Arch. Toxicol. 2010, 84:787-798.
16. Emmett E.A., Zhang H., Shofer F.S., Freeman D., Rodway N.V., Desai C., Shaw L.M. Community exposure to perfluorooctanoate: relationships between serum levels and certain health parameters. J. Occup. Environ. Med. 2006, 48:771-779.
17. Eriksen K.T., Sorensen M., McLaughlin J.K., Lipworth L., Tjonneland A., Overvad K., Raaschou-Nielsen O. Perfluorooctanoate and perfluorooctanesulfonate plasma levels and risk of cancer in the general Danish population. J. Natl. Cancer Inst. 2009, 101:605-609.
18. Eustis S.L., Boorman G.A. Proliferative lesions of the exocrine pancreas: relationship to corn oil gavage in the National Toxicology Program. J. Natl. Cancer Inst. 1985, 75:1067-1073.
19. Eustis S.L., Boorman G.A. Exocrine pancreas. Pathology of the Fischer Rat 1990, 95-108. Chapter 8, Academic Press, Inc., San Diego. G.A. Boorman, S.L. Eustis, M.R. Elwell, C.A. Montgomery, W.F. Mackenzie (Eds.).
20. Fleiss J.L. Statistical Methods for Rates and Proportions 1973, John Wiley and Sons, New York.
21. Frame, S.R., McConnell, E.E., 2003. October 16, 2003 report: review of proliferative lesions the exocrine pancreas in two chronic feeding studies in rats with ammonium perfluorooctanoate. DuPont Laboratory Project Identification DuPont-13788, Haskell Laboratory for Health and Environmental Sciences, E.I. DuPont de Nemours and Company, Newark, DE, USA. U.S. EPA Administrative Record No. AR226-1920.
22. Gervois P., Kleemann R., Pilon A., Percevault F., Koenig W., Staels B., Kooistra T. Global suppression of IL-6-induced acute phase response gene expression after chronic in vivo treatment with the peroxisome proliferator-activated receptor-alpha activator fenofibrate. J. Biol. Chem. 2004, 279:16154-16160.
23. Greaves P., Faccini J.M. Digestive system. Pancreas. Rat Histopathology 1992, Elsevier, London, pp. 118-126. second ed.
24. Griffith F.D., Long J.E. Animal toxicity studies with ammonium perfluorooctanoate. Am. Ind. Hyg. Assoc. J 1980, 41:576-583.
25. Hansen J.F., Ross P.E., Makovec G.T., Eustis S.L., Sigler R.E. Proliferative and other selected lesions of the exocrine pancreas in rats. GI-6. Guides for Toxicologic Pathology 1995, STP/ARP/AFTP, Washington, DC.
26. Hardisty J.F., Wilson G.A., Brown W.R., McConnell E.E., Frame S.R., Gaylor D.W., Kennedy G.L., Butenhoff J.L. Pathology Working Group review and evaluation of proliferative lesions of mammary gland tissues in female rats fed ammonium perfluorooctanoate (APFO) in the diet for 2 years. Drug Chem. Toxicol. 2010, 33:131-137.
27. Hirose Y., Nagahori H., Yamada T., Deguchi Y., Tomigahara Y., Nishioka K., Uwagawa S., Kawamura S., Isobe N., Lake B.G., Okuno Y. Comparison of the effects of the synthetic pyrethroid Metofluthrin and phenobarbital on CYP2B form induction and replicative DNA synthesis in cultured rat and human hepatocytes. Toxicology 2009, 258:64-69.
28. IARC, 2001. IARC monographs on the evaluation of carcinogenic risks to humans. Some Thyrotropic Agents, vol. 79. IARC Press, Lyon.
29. Johansson N., Benford D., Carere A., De Boer J., Dellatte E., De Voogt P., Di Domenico A., Heppner C.W., Schoeters G., Schrenk D. EFSA's risk assesment on PFOS and PFOA in the food. Toxicol. Lett. 2009, 189:S42.
30. Keenan K.P., Ballam G.C., Soper K.A., Laroque P., Coleman J.B., Dixit R. Diet, caloric restriction, and the rodent bioassay. Toxicol. Sci. 1999, 52:24-34.
31. Kennedy G.L., Butenhoff J.L., Olsen G.W., O'Connor J.C., Seacat A.M., Perkins R.G., Biegel L.B., Murphy S.R., Farrar D.G. The toxicology of perfluorooctanoate. Crit. Rev Toxicol. 2004, 34:351-384.
32. Klaunig J.E., Babich M.A., Baetcke K.P., Cook J.C., Corton J.C., David R.M., DeLuca J.G., Lai D.Y., McKee R.H., Peters J.M., Roberts R.A., Fenner-Crisp P.A. PPARalpha agonist-induced rodent tumors: modes of action and human relevance. Crit. Rev Toxicol. 2003, 33:655-780.
33. Kudo N., Kawashima Y. Toxicity and toxicokinetics of perfluorooctanoic acid in humans and animals. J. Toxicol. Sci. 2003, 28:49-57.
34. Lake B.G. Species differences in the hepatic effects of inducers of CYP2B and CYP4A subfamily forms: relationship to rodent liver tumour formation. Xenobiotica 2009, 39:582-596.
35. Lau C., Anitole K., Hodes C., Lai D., Pfahles-Hutchens A., Seed J. Perfluoroalkyl acids: a review of monitoring and toxicological findings. Toxicol. Sci. 2007, 99:366-394.
36. Leonard R.C., Kreckmann K.H., Sakr C.J., Symons J.M. Retrospective cohort mortality study of workers in a polymer production plant including a reference population of regional workers. Ann. Epidemiol. 2008, 18:15-22.
37. Liu R.C., Hahn C., Hurtt M.E. The direct effect of hepatic peroxisome proliferators on rat Leydig cell function in vitro. Fundam. Appl. Toxicol. 1996, 30:102-108.
38. Liu R.C., Hurtt M.E., Cook J.C., Biegel L.B. Effect of the peroxisome proliferator, ammonium perfluorooctanoate (C8), on hepatic aromatase activity in adult male Crl:CD BR (CD) rats. Fundam. Appl. Toxicol. 1996, 30:220-228.
39. Longnecker D.S., Millar P.M. Tumours of the pancreas. Tumours of the Rat 1990, vol. I:241-249. International Agency for Research on Cancer, Lyon. second ed. V. Turusov (Ed.).
40. Lundin J.I., Alexander B.H., Olsen G.W., Church T.R. Ammonium perfluorooctanoate production and occupational mortality. Epidemiology 2009, 20:921-928.
41. Mann, P.C., Frame, S.R., 2004. June 25, 2004 report: FC-143: two year oral toxicity-oncogenicity study in rats - peer review of ovaries. DuPont Laboratory Identification DuPont-15261, Haskell Laboratory for Health and Environmental Sciences, E.I DuPont de Nemours and Company, Newark, DE, USA. U.S. EPA Administrative Record No. AR226-1921.
42. Maronpot R.R., Montgomery C.A., Boorman G.A., McConnell E.E. National Toxicology Program nomenclature for hepatoproliferative lesions of rats. Toxicol. Pathol. 1986, 14:263-273.
43. McGuinness E.E., Morgan R.G., Levison D.A., Frape D.L., Hopwood D., Wormsley K.G. The effects of long-term feeding of soya flour on the rat pancreas. Scand. J. Gastroenterol. 1980, 15:497-502.
44. Nakamura T., Ito Y., Yanagiba Y., Ramdhan D.H., Kono Y., Naito H., Hayashi Y., Li Y., Aoyama T., Gonzalez F.J., Nakajima T. Microgram-order ammonium perfluorooctanoate may activate mouse peroxisome proliferator-activated receptor α, but not human PPARα. Toxicology 2009, 265:27-33.
45. Olsen G.W., Zobel L.R. Assessment of lipid, hepatic, and thyroid parameters with serum perfluorooctanoate (PFOA) concentrations in fluorochemical production workers. Int. Arch. Occup. Environ. Health 2007, 81:231-246.
46. Olsen J.H., Boice J.D., Jensen J.P., Fraumeni J.F. Cancer among epileptic patients exposed to anticonvulsant drugs. J. Natl. Cancer Inst. 1989, 81:803-808.
47. Olsen J.H., Schulgen G., Boice J.D., Whysner J., Travis L.B., Williams G.M., Johnson F.B., McGee J.O. Antiepileptic treatment and risk for hepatobiliary cancer and malignant lymphoma. Cancer Res. 1995, 55:294-297.
48. Perkins R.G., Butenhoff J.L., Kennedy G.L., Palazzolo M.J. 13-week dietary toxicity study of ammonium perfluorooctanoate (APFO) in male rats. Drug Chem. Toxicol. 2004, 27:361-378.
49. Ross J., Plummer S.M., Rode A., Scheer N., Bower C.C., Vogel O., Henderson C.J., Wolf C.R., Elcombe C.R. Human constitutive androstane receptor (CAR) and pregnane X receptor (PXR) support the hypertrophic but not the hyperplastic response to the murine nongentoxic hepatocarcinogens phenobarbital and chlordane in vivo. Toxicol. Sci. 2010, 116:452-466.
50. Sellers R.S., Morton D., Michael B., Roome N., Johnson J.K., Yano B.L., Perry R., Schafer K. Society of Toxicologic Pathology position paper: organ weight recommendations for toxicology studies. Toxicol. Pathol. 2007, 35:751-755.
51. Whysner J., Ross P.M., Williams G.M. Phenobarbital mechanistic data and risk assessment: enzyme induction, enhanced cell proliferation, and tumor promotion. Pharmacol. Ther. 1996, 71:153-191.
52. Yang Q., Nagano T., Shah Y., Cheung C., Ito S., Gonzalez F.J. The PPAR{alpha}-humanized mouse: a model to investigate species differences in liver toxicity mediated by PPAR{alpha}. Toxicol. Sci. 2008, 101:132-139.